Ex-Teleos CEO Rosenberg to Steer Atlas Startup Rodin

Xconomy Boston — 

Adam Rosenberg has been named the CEO of Cambridge, MA-based Rodin Therapeutics, a startup seeded by Atlas Venture in 2013 and run, up until now, by Atlas partner Bruce Booth. Rosenberg was previously the CEO of Medford, MA-based Telos Therapeutics, a startup developing small molecule drugs for neurological disorders. He’ll remain in charge of Teleos until the company hires a successor. Rodin, meanwhile, is developing an epigenetic drug—an inhibitor of histone deacetylase 2 (HDAC2)—as a potential cognitive booster for neurodegenerative diseases like Alzheimer’s, Parkinson’s and post traumatic stress disorder.